BV reported Q2 fiscal 2026 results on May 5th — and the print was a split verdict. Revenue topped estimates and full-year guidance moved higher, but EPS came in light. That combination explains the week: the stock closed at $11.81, up 1.6% on the day of results but down 4.4% on the week, as investors weighed the guidance lift against the profit miss.
Options traders have grown notably more bullish into the period. The put/call ratio dropped to 0.78, nearly a full standard deviation below its 20-day average of 1.12. Six weeks ago the ratio was running above 1.55, reflecting heavy downside hedging. That shift to call dominance was a meaningful repositioning ahead of earnings — the lending market reinforced a calm picture, with borrow availability at normal levels, cost to borrow at just 0.44% annualised, and the short score sitting at a mid-range 45.4. None of that points to a squeeze setup or an aggressively crowded short.
Short interest itself tells a nuanced story. At 3.9% of the free float — up 31% from a month ago — it has been building, but the absolute level is not extreme. The rise accelerated sharply in mid-April, from roughly 2.7 million shares short around April 9 to 3.7 million by the end of the month. That pickup preceded earnings rather than following them, suggesting shorts were positioned for a weak print. The small pullback in short interest this week, down less than 1%, hints at limited conviction to press further after the revenue beat.
The Street remains cautiously constructive but has been trimming ambitions. Five analysts carry buy-equivalent ratings, with the consensus mean target at $16.26 — a 38% premium to Tuesday's close. The most recent named moves were from Morgan Stanley, which raised its target to $14 in early March while staying at Equal-Weight, and from JP Morgan, which lifted its target to $13 in February while maintaining Underweight. Goldman Sachs carries a Sell with a $10.50 target. That spread — bulls above $15, Goldman below the current price — captures the ongoing debate: BrightView is a services business with improving revenue momentum (the company now guides for 2026 revenue of $2.745B–$2.795B and raised its land-segment growth outlook to 2–3%), but margin delivery has been inconsistent. The EV/EBITDA multiple at 6.6x is undemanding for the sector. EPS momentum scores rank in the 79th percentile on a 90-day forward basis, and the 12-month forward EPS growth rank also sits at 79 — both suggesting the earnings trajectory is improving in analyst models even if the current quarter disappointed on the bottom line.
KKR holds 22.9% of shares outstanding, a legacy of the company's 2018 IPO. Among active managers, Dimensional added 155,000 shares in Q1 2026 and Van Berkom held above 5% as of year-end 2025. Harvey Partners trimmed 340,000 shares in that same period, and Newtyn reduced its position by roughly 200,000. The insider ledger is quiet in aggregate — the most recent open-market purchase was director William Cornog buying 5,000 shares at $13.46 in early February, following a $128K buy at $12.84 in December 2025. Neither is large, but both came at prices well above where the stock now trades.
The next focal point is whether management can close the gap between revenue momentum and margin improvement. The guidance raise on the top line reset expectations higher; what the market watches next is whether the earnings line follows.
See the live data behind this article on ORTEX.
Open BV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
